Department of Orthopaedics, Beijing Tongren Hospital, Beijing, China.
Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia.
IUBMB Life. 2020 May;72(5):1054-1064. doi: 10.1002/iub.2248. Epub 2020 Feb 11.
Rheumatoid arthritis (RA) is associated with joint damage. Effectiveness of embelin has been established in a wide variety of inflammatory disorders, but its utility as a therapeutic agent is limited by its poor absorption, rapid metabolism, and fast systemic elimination. To apprehend these limitations, we propose to use highly bioavailable embelin-loaded chitosan nanoparticles (CS-embelin NPs) for the treatment of RA.
The rats were made arthritic using a subcutaneous injection with 0.1 ml complete Freund's adjuvant (CFA) into the footpad of the left hind paw. CS-embelin NPs (25 and 50 mg/kg) was administered from day 15 to day 28 after adjuvant injection. After the experimental period, the animals were sacrificed and various biochemical markers were assessed.
Arthritic score and paw swelling were significantly reduced after treatment with CS-embelin NPs. Arthritis-induced rats showed a significant increase in malondialdehyde (MDA) and nitric oxide (NO) with a concomitant reduction of antioxidants in the paw tissue. CS-embelin NPs (25 and 50 mg/kg) reduced MDA and NO levels and restored antioxidant levels to normalcy by mitigating oxidative stress. The arthritic rats exhibited elevated tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1beta (IL-1β) serum concentrations, upregulated TNF- α and IL-6 protein levels and upregulated nuclear factor-kB (NF-kB) mRNA expression in paw tissues. Treatment with CS-embelin NPs (25 and 50 mg/kg) significantly reduced serum levels and down-regulated inflammatory markers to normalcy, dose-dependently.
The results suggest that CS-embelin NPs displayed a protective effect against adjuvant-induced arthritis in rats mediated through antioxidant and anti-inflammatory effects.
类风湿性关节炎(RA)与关节损伤有关。由于具有广泛的抗炎作用,因而已经确立了蛇葡萄素的有效性,但由于其吸收不良、代谢迅速和全身消除迅速,因此其作为治疗剂的用途受到限制。为了克服这些局限性,我们建议使用高生物利用度的负载蛇葡萄素的壳聚糖纳米粒子(CS-embelin NPs)治疗 RA。
通过向左后足垫皮下注射 0.1ml 完全弗氏佐剂(CFA)使大鼠发生关节炎。在佐剂注射后第 15 天至第 28 天给予 CS-embelin NPs(25 和 50mg/kg)。实验结束后,处死动物并评估各种生化标志物。
用 CS-embelin NPs 治疗后,关节炎评分和足肿胀明显减轻。关节炎诱导的大鼠的爪组织中的丙二醛(MDA)和一氧化氮(NO)显著增加,同时抗氧化剂减少。CS-embelin NPs(25 和 50mg/kg)降低 MDA 和 NO 水平,并通过减轻氧化应激使抗氧化剂水平恢复正常。关节炎大鼠的血清肿瘤坏死因子-α(TNF-α),白细胞介素-6(IL-6)和白细胞介素-1β(IL-1β)浓度升高,TNF-α和 IL-6 蛋白水平上调,核因子-kB(NF-kB)mRNA 表达上调。CS-embelin NPs(25 和 50mg/kg)治疗可显著降低血清水平,并使炎症标志物呈剂量依赖性恢复正常。
结果表明,CS-embelin NPs 通过抗氧化和抗炎作用对大鼠佐剂性关节炎表现出保护作用。